Research Abstract
I have been conducting predictive and/or prognostic biomarker analyses of lung cancer by immunohistochemistry or in situ hybridization. I have also been involved in multiple studies to investigate mechanisms of resistance to tyrosin kinase inhibitors in driver mutation positive non-small cell lung cancer patients in collaboration with thoracic oncologists and basic researchers. In the field of the pancreas, I have been leading and collaborating with clinical colleagues in clinicopathological and translational studies of pancreatic intraductal papillary mucinous neoplasms (IPMNs). My current research focus in this field is to investigate differences in clinicopathological and molecular characteristics and outcomes between different epithelial subtypes of IPMN and biomarkers that can differentiate high risk IPMN lsions (that need to be surgically resected) from those with a low risk of malignat potential (that can be followed without surgical intervention).